Tevogen Bio, a clinical-stage biotech company, announced on Thursday it plans to go public via a merger with special purpose acquisition company (SPAC) Semper Paratus Acquisition.
The merger, valued at about $1.2 billion, is expected to conclude in the fourth quarter of this year, at which point...
This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.
